CoChat
Sign Up
Cited by 1,228Atrial Fibrillation Management and OutcomesAntiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Open access
Lopes, Renato D., Heizer, Gretchen, Aronson, Ronald, Vora, Amit N., Massaro, Tyler, Mehran, Roxana, Goodman, Shaun G., Windecker, Stephan, Darius, Harald, Li, Jia, Averkov, Oleg, Bahit, M. Cecilia, Berwanger, Otavio, Budaj, Andrzej, Hijazi, Ziad, Parkhomenko, Alexander, Sinnaeve, Peter, Storey, Robert F., Thiele, Holger, Vinereanu, Dragos, Granger, Christopher B., Alexander, John H.·2019·New England Journal of Medicine
DOI 10.1056/nejmoa1817083
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. METHODS: inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. RESULTS: Enrollment included 4614 patients from 33 countries. There were no significant interactions between the two randomization factors on the primary or secondary outcomes. Major or clinically relevant nonmajor bleeding was noted in 10.5% of the patients receiving apixaban, as compared with 14.7% of those receiving a vitamin K antagonist (hazard ratio, 0.69; 95% confidence interval [CI], 0.58 to 0.81; P<0.001 for both noninferiority and superiority), and in 16.1% of the patients receiving aspirin, as compared with 9.0% of those receiving placebo (hazard ratio, 1.89; 95% CI, 1.59 to 2.24; P<0.001). Patients in the apixaban group had a lower incidence of death or hospitalization than those in the vitamin K antagonist group (23.5% vs. 27.4%; hazard ratio, 0.83; 95% CI, 0.74 to 0.93; P = 0.002) and a similar incidence of ischemic events. Patients in the aspirin group had an incidence of death or hospitalization and of ischemic events that was similar to that in the placebo group. CONCLUSIONS: inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a vitamin K antagonist, aspirin, or both. (Funded by Bristol-Myers Squibb and Pfizer; AUGUSTUS ClinicalTrials.gov number, NCT02415400.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1817083

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

Sorted by citations

Items 201–300 of 1,000

Related

See all

Metadata

Authors
Lopes, R. D., Heizer, G., Aronson, R., Vora, A. N., Massaro, T., Mehran, R., Goodman, S. G., Windecker, S., Darius, H., Li, J., Averkov, O., Bahit, M. C., Berwanger, O., Budaj, A., Hijazi, Z., Parkhomenko, A., Sinnaeve, P., Storey, R. F., Thiele, H., Vinereanu, D., Granger, C. B., & Alexander, J. H.
Affiliations
  • From the Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L., G.H., A.N.V., T.M., C.B.G., J.H.A.); Bristol-Myers Squibb, Princeton, NJ (R.A., J.L.); Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, and Cardiovascular Research Foundation, New York (R.M.); Canadian VIGOUR Centre, University of Alberta, Edmonton (S.G.G.), and the Terrence Donnelly Heart Centre, St. Michael’s Hospital, University of Toronto, Toronto (S.G.G...
  • St. Michael's Hospital (CA)
  • Uppsala University (SE)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2019-04-18
Volume
380
Issue
16
Pages
1509-1524
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1817083
OpenAlex
W2921724943
Cited by
1,228
References
32
Citations by year
2026: 116 · 2025: 109 · 2024: 112 · 2023: 124 · 2022: 159 · 2021: 215 · 2020: 241 · 2019: 151
FWCI
138.39
Type
journal article
Language
en
Open access
Licence
www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
  • BORIS (University Library Bern) (submittedVersion)
  • Digital Access to Libraries (submittedVersion, other-oa)
  • Lirias (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • Pfizer
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
atrial fibrillation, acute coronary syndrome, percutaneous coronary intervention, antithrombotic therapy, apixaban, vitamin K antagonists, aspirin, bleeding risk, ischemic events, non-inferiority, hospitalization
MeSH terms
Aged, Aged, 80 and over, Anticoagulants, Aspirin, Atrial Fibrillation, Double-Blind Method, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Pyrazoles, Pyridones, Vitamin K, Acute Coronary Syndrome, Purinergic P2Y Receptor Antagonists, Percutaneous Coronary Intervention, Factor Xa Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review